Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by equities researchers at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, The Fly reports.
A number of other equities research analysts have also recently commented on VNDA. Jefferies Financial Group increased their target price on shares of Vanda Pharmaceuticals from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, December 4th. Stifel Nicolaus set a $36.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, December 3rd. Oppenheimer reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday, December 3rd. Citigroup increased their target price on shares of Vanda Pharmaceuticals from $31.00 to $47.00 and gave the company a “buy” rating in a research report on Friday, December 7th. Finally, JMP Securities increased their target price on shares of Vanda Pharmaceuticals from $36.00 to $52.00 and gave the company a “market outperform” rating in a research report on Thursday, December 6th. Five investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Vanda Pharmaceuticals has an average rating of “Buy” and an average target price of $38.38.
Vanda Pharmaceuticals stock opened at $25.06 on Wednesday. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -71.60, a P/E/G ratio of 0.75 and a beta of 0.70. Vanda Pharmaceuticals has a 1 year low of $13.88 and a 1 year high of $33.44.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.18. Vanda Pharmaceuticals had a net margin of 7.06% and a return on equity of 5.88%. The company had revenue of $49.13 million during the quarter, compared to analysts’ expectations of $49.44 million. During the same period in the previous year, the company earned ($0.03) EPS. The firm’s quarterly revenue was up 18.9% on a year-over-year basis. As a group, equities research analysts anticipate that Vanda Pharmaceuticals will post 0.21 earnings per share for the current year.
In other Vanda Pharmaceuticals news, CFO James Patrick Kelly sold 6,061 shares of the company’s stock in a transaction that occurred on Thursday, January 3rd. The shares were sold at an average price of $26.37, for a total transaction of $159,828.57. Following the transaction, the chief financial officer now owns 196,221 shares in the company, valued at approximately $5,174,347.77. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Gian Piero Reverberi sold 1,130 shares of the company’s stock in a transaction that occurred on Wednesday, January 2nd. The shares were sold at an average price of $26.59, for a total transaction of $30,046.70. Following the transaction, the senior vice president now owns 136,569 shares in the company, valued at approximately $3,631,369.71. The disclosure for this sale can be found here. Insiders have sold a total of 22,427 shares of company stock worth $591,496 in the last 90 days. 7.80% of the stock is currently owned by company insiders.
A number of institutional investors have recently modified their holdings of the business. LS Investment Advisors LLC increased its stake in shares of Vanda Pharmaceuticals by 109.3% in the fourth quarter. LS Investment Advisors LLC now owns 3,662 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 1,912 shares during the period. Crossmark Global Holdings Inc. acquired a new stake in shares of Vanda Pharmaceuticals in the fourth quarter worth $224,000. United Services Automobile Association acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter worth $211,000. SG Americas Securities LLC acquired a new stake in shares of Vanda Pharmaceuticals in the fourth quarter worth $266,000. Finally, Meeder Asset Management Inc. boosted its holdings in Vanda Pharmaceuticals by 164.6% during the third quarter. Meeder Asset Management Inc. now owns 11,417 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 7,102 shares in the last quarter. Institutional investors and hedge funds own 99.37% of the company’s stock.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Read More: How does a reverse stock split work?
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.